allergy banner

Videos


Open Access Agreements with Wiley



Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Free access

Articles


Outcomes of Covid19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders

Giannetti, M.P., Olivieri, F., Godwin, G., et al. Allergy. First published: 13 August 2022

Alarming inflammation: the TGFβ1–Nrp1 pathway upregulates the IL-33 axis in lung ILC2s

Salvati, L. and Mazzoni, A. Allergy. First published: 12 August 2022

Association between EBV reactivation and development of Long-COVID fatigue

Rohrhofer, J., Graninger, M., Lettenmaier, L., et al. Allergy. First published: 11 August 2022

Biologics and airway aemodeling in severe asthma

Varricchi, G., Ferri, S., Pepys, J., et al. Allergy. First published: 11 August 2022

Reliability of the electro-medical device Nexkin DSPT® for wheal size measurement in allergy skin testing: An exploratory clinical trial

Morales-Palacios, M.P., Núñez-Córdoba, J.M., Tejero, E., et al. Allergy. First published: 11 August 2022

Murine lung cDC1s inhibit memory Th2 cell generation by reducing CD62L+ memory precursors via IL-12

Liu, J., Du, L., Yi, S., et al. Allergy. First published: 07 August 2022

Reply to correspondence to ‘Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus’

Hagemann, J., Zuberbier, T., Walter Canonica, G., et al. Allergy. First published: 06 August 2022

The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model

Kothari, A., Hirschmugl, B., Lee, J.-S., et al. First published: 04 August 2022

The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy

Sasaki, M., Schwab, C., Ramirez Garcia, A., et al. Allergy. First published: 02 August 2022

Biostatistics in Allergy - recommendations for authors

Ordak, M. Allergy. First published: 02 August 2022

Fel d 1 surface expression on plant-made eBioparticles combines potent immune activation and hypo-allergenicity

Busold, S., Aglas, L., Menage, C., et al. Allergy. First published: 02 August 2022

CEACAM5 is an IL-13-regulated epithelial gene that mediates transcription in type-2 (T2) high severe asthma

Mumby, S., Kermani, N.Z., Garnett, J.P., et al. Allergy. First published: 02 August 2022

Human neutrophils require short exposure to cytokines and allergen to become functional antigen-presenting cells

Polak, D., Elbe-Bürger, A., Kitzmüller, C., Zlabinger, G.J. and Bohle, B. Allergy. First published: 01 August 2022

Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines

Palomares, F., Paris, J.L., Labella, M., Doña, I., Mayorga, C. and Torres, M.J. Allergy. First published: 01 August 2022

Citations: 1574

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Citations: 470

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

Citations: 274

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Xia, Z. et al. Allergy. 2020; 75: 1742– 1752

Citations: 249

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Citations: 241

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Radzikowska, U., Ding, M., Tan, G., Zhakparov, D., Peng, Y., Wawrzyniak, P. et al. Allergy. 2020; 75: 2828– 2844

Citations: 175

Eleven faces of coronavirus disease 2019

Dong, X., Cao, Y.-Y., Lu, X.-X., Zhang, Du, H., J.-J., Yan, Y.-Q. et al. Allergy. 2020; 75: 1699– 1709

Citations: 115

Type 2 immunity in the skin and lungs

Akdis, CA, Arkwright, PD, Brüggen, MC, et al. Allergy. 2020; 75: 1582– 1605

Citations: 87

Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2

Zhang, J.-j., Cao, Y.-y., Dong, X., Wang, B.-c., Liao, M.-y., Lin, J. et al. Allergy. 2020; 75: 1809-1812

Citations: 69

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Bousquet, J., Akdis, C.,A., Jutel, M., Bachert, C., Klimek, L., Agache, I. et al. Allergy. 2020; 75: 2440-2444

Citations: 69

Towards a more precise diagnosis of hypersensitivity to beta-lactams — an EAACI position paper

Romano, A, Atanaskovic-Markovic, M, Barbaud, A, et al. Allergy. 2020; 75: 1300– 1315

Citations: 69

Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?

Gursel, M. and Gursel, I. Allergy. 2020; 75: 1815-1819

The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Advances and recent developments in asthma in 2020

Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update

Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541

Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines

Palomares, F., Paris, J.L., Labella, M., Doña, I., Mayorga, C. and Torres, M.J. Allergy. First published: 01 August 2022

Exposure to avian coronavirus vaccines is associated with increased levels of SARS-CoV-2-cross-reactive antibodies

Ardicli, O, Carli, KT, Satitsuksanoa, P, et al. et al. Allergy. First published: 23 July 2022

Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry

Anvari, S., Samarakoon, U., Fu, X., et al. Allergy. First published: 16 July 2022

The nasopharyngeal and salivary microbiomes in COVID-19 patients with and without asthma

Kim, J.G., Zhang, A., Rauseo, A.M., et al. Allergy. First published: 15 July 2022

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Worm, M., Alexiou, A., Bauer, A., et al. Allergy. First published: 20 June 2022

Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection

Maurer, D.J., Barletta, E., Heider, A., et al. Allergy. First published: 12 June 2022

T cell recovery and evidence of persistent immune activation 12 months after severe COVID-19

Taeschler, P., Adamo, S., Deng, Y., et al. Allergy. First published: 14 May 2022

Long-term effects of homologous and heterologous SARS-CoV-2 vaccination on humoral and cellular immune responses

Hollstein, M.M., Münsterkötter, L., Schön, M.P., et al. Allergy. First published: 14 May 2022

COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab

Francis, C.H.R., Hearn, A.P., Ratnakumar, S., et al. Allergy. First published: 01 May 2022

Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern

Rothen, D.A., Krenger, P.S., Nonic, A., et al. Allergy. First published: 11 April 2022

Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures

Taeschler, P., Cervia, C., Zurbuchen, Y., et al. Allergy. First published: 01 April 2022

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

Gattinger, P., Kratzer, B., Tulaeva, I., et al. Allergy. First published: 31 March 2022

Are health care policies for COVID-19 evidence-based?

Bonini, S. and Fiorito, S. Allergy. First published: 30 March 2022

Virus-related stimuli modulate SARS-CoV-2 entry factor expression in pediatric tonsillar epithelial cells in vitro

Hara, M., Morimoto, N., Watabe, T., et al. Allergy. First published: 29 March 2022

Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?

Eberlein, B., Sonja, M., Fischer, J., Darsow, U., Biedermann, T. and Brockow, K. Allergy. First published: 10 March 2022

Humoral immune response of Sinopharm/BBIBP COVID-19 vaccination before and after the booster immunization

Cheng, Z.J., Huang, H., Zheng, P., et al. Allergy. First published: 07 March 2022

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review

Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016

Eczema herpeticum in atopic dermatitis

Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027

Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study

Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052

Direct assessment of individual skin barrier components by electrical impedance spectroscopy

Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132

Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis

Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193

Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma

Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202

Identification of Ulocladium chartarum as an important indoor allergen source

Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206

Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis

Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214

Legends of allergy and immunology: Sergio Bonini

Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229

Medical algorithm: Peri-operative management of mastocytosis patients

Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235

Junior Members Corner



Dear Junior Members,



EAACI Hybrid Congress 2022



The EAACI annual congress 2022 was held on 1-3 July with a hybrid format. Online and in person in Prague, Czech Republic. The event was a solid success! Onsite attendance reached 4,500 delegates, while 3,000 delegates tuned it from all 5 continents - over 100 countries represented in a diverse and extremely rich audience. The congress delivered more than 80 scientific sessions as part of an extensive program tailored to offer the most advanced research available in our specialty.

The meeting represented a wonderful opportunity for the EAACI Junior Members (JM) to improve their knowledge and expand their collaborative network. During the congress, the JMA organized several activities dedicated to the juniors:

On Friday, 01 July 2022, in the JM Scientific Symposium “Exploring the AXIS communications in allergy and chronic diseases” the speakers, Riccardo Castagnoli, Elisabeth Tham and Giada De Palma presented the complex interplays that characterize the immune-gut, the skin-gut and the brain-gut axis.

On Saturday, 02 July 2022, during the Educational Session, Cezmi Akdis, Thomas Eiwegger, and Anna Globinska instructed the audience with helpful advice to improve paper writing skills, better deal with peer-review process and graphically represent the results. Moreover, several JM were able to present their data at the JM Case report session and JM Poster session.

The congress also represented the opportunity to meet the students who attended the EAACI Allergy College. EAACI is doing a tremendous effort to promote education on Allergology among students and fellows around the world. The Allergy College program gives to undergraduate students the possibility to collaborate with mentors, selected for their prominent expertise. These collaborations were extremely fruitful with many students actively involved in the congress.

In addition, during the congress, the EAACI Knowledge Hub was launched. It represents a fresh and interactive digital platform where scientific and educational resources are made available to the EAACI members. In the EAACI Knowledge Hub it is possible to read the latest research in terms of guidelines, books, journals, position papers and much more… we encourage you to explore it!

Moreover, on Saturday, 02 July 2022, the new Molecular Allergology User’s Guide 2.0 was presented. After the success of the first edition of “EAACI Molecular Allergology User’s Guide”, the new Molecular Allergology User’s Guide 2.0 provides state-of-the-art information on allergen molecules, their clinical relevance and application in diagnostic algorithms for clinical practice. You can find more about Molecular Allergology User’s Guide 2 by clicking here

Finally, the initiative “Beat Allergy Run & Walk in Prague!” represented a way to to raise awareness about allergy and a great opportunity for JM to meet each other running.

The 2022 annual congress has been a wonderful experience! It might be over, but we are already looking forward to meeting again in Hamburg, Germany and online on June 9-11 at the EAACI Hybrid Congress 2023!



JSAM Digital Platform



EAACI junior members

Best regards,
The Junior Member Assembly